Monica Di Luca

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8281610/publications.pdf

Version: 2024-02-01

182 papers	10,233 citations	19636 61 h-index	43868 91 g-index
190 all docs	190 docs citations	190 times ranked	11518 citing authors

#	Article	IF	Citations
1	Synaptic dysfunction in early phases of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 417-438.	1.0	27
2	Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinsonâ€™s and Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 1539.	1.8	10
3	The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimerâ€™s disease. Molecular Therapy, 2022, 30, 2474-2490.	3.7	15
4	NMDA and AMPA Receptor Autoantibodies in Brain Disorders: From Molecular Mechanisms to Clinical Features. Cells, 2021, 10, 77.	1.8	20
5	ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2416.	1.8	17
6	Protein-protein interactions at the NMDA receptor complex: From synaptic retention to synaptonuclear protein messengers. Neuropharmacology, 2021, 190, 108551.	2.0	22
7	Looking at Alzheimerâ€™s Disease Pathogenesis from the Nuclear Side. Biomolecules, 2021, 11, 1261.	1.8	3
8	Cyclase-associated protein 2 dimerization regulates cofilin in synaptic plasticity and Alzheimer's disease. Brain Communications, 2020, 2, fcaa086.	1.5	29
9	Proximity ligation assay reveals both pre- and postsynaptic localization of the APP-processing enzymes ADAM10 and BACE1 in rat and human adult brain. BMC Neuroscience, 2020, 21, 6.	0.8	18
10	Synaptic GluN2A-Containing NMDA Receptors: From Physiology to Pathological Synaptic Plasticity. International Journal of Molecular Sciences, 2020, 21, 1538.	1.8	69
11	Differential mechanisms of tolerance induced by NMDA and 3,5â€dihydroxyphenylglycine (DHPG) preconditioning. Journal of Neurochemistry, 2020, 155, 638-649.	2.1	8
12	Linking NMDA Receptor Synaptic Retention to Synaptic Plasticity and Cognition. IScience, 2019, 19, 927-939.	1.9	31
13	The Synaptonuclear Messenger RNF10 Acts as an Architect of Neuronal Morphology. Molecular Neurobiology, 2019, 56, 7583-7593.	1.9	12
14	Amyloid-Î² Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena. Molecular Neurobiology, 2019, 56, 7136-7143.	1.9	9
15	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. Biomedicine and Pharmacotherapy, 2019, 113, 108661.	2.5	52
16	NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. Neurobiology of Disease, 2019, 121, 338-349.	2.1	24
17	Synapse-to-nucleus communication: from developmental disorders to Alzheimer's disease. Current Opinion in Neurobiology, 2018, 48, 160-166.	2.0	34
18	Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin. Journal of Alzheimer's Disease, 2018, 62, 1113-1123.	1.2	29

#	Article	IF	Citations
19	A light-gated potassium channel for sustained neuronal inhibition. Nature Methods, 2018, 15, 969-976.	9.0	47
20	microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 113-123.	1.2	64
21	ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 2017, 21, 1017-1026.	1.5	43
22	Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiology of Disease, 2017, 108, 54-64.	2.1	40
23	Coxsackievirus Adenovirus Receptor Loss Impairs Adult Neurogenesis, Synapse Content, and Hippocampus Plasticity. Journal of Neuroscience, 2016, 36, 9558-9571.	1.7	29
24	LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias. Molecular Brain, 2016, 9, 53.	1.3	9
25	Ring finger protein 10 is a novel synaptonuclear messenger encoding activation of NMDA receptors in hippocampus. ELife, 2016, 5, e12430.	2.8	39
26	NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. Frontiers in Cellular Neuroscience, 2015, 9, 245.	1.8	68
27	Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex. Nature Communications, 2015, 6, 10181.	5.8	59
28	Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome. Neuron, 2015, 87, 382-398.	3.8	59
29	Zinc transporterâ€1: a novel <scp>NMDA</scp> receptorâ€binding protein at the postsynaptic density. Journal of Neurochemistry, 2015, 132, 159-168.	2.1	47
30	Targeting glutamatergic synapses in Parkinson's disease. Current Opinion in Pharmacology, 2015, 20, 24-28.	1.7	27
31	Elongation factor-2 phosphorylation in dendrites and the regulation of dendritic mRNA translation in neurons. Frontiers in Cellular Neuroscience, 2014, 8, 35.	1.8	84
32	ADAM10 in Synaptic Physiology and Pathology. Neurodegenerative Diseases, 2014, 13, 72-74.	0.8	24
33	Early maternal deprivation immunologically primes hippocampal synapses by redistributing interleukin-1 receptor type I in a sex dependent manner. Brain, Behavior, and Immunity, 2014, 35, 135-143.	2.0	37
34	Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4375-84.	3.3	26
35	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiology of Disease, 2013, 52, 229-236.	2.1	155
36	Modeling Alzheimerâ€™s disease: from past to future. Frontiers in Pharmacology, 2013, 4, 77.	1.6	40

#	Article	IF	Citations
37	Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimerâ€™s disease. Journal of Clinical Investigation, 2013, 123, 2523-2538.	3.9	96
38	The neuropeptide <u>PACAP38</u> induces dendritic spine remodeling through ADAM10/N-Cadherin signaling pathway. Journal of Cell Science, 2012, 125, 1401-6.	1.2	29
39	N-Methyl-d-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons. Journal of Biological Chemistry, 2012, 287, 18103-18114.	1.6	38
40	SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. Neurobiology of Aging, 2012, 33, 422.e1-422.e10.	1.5	46
41	Reply to â€œDiagnosis of progressive supranuclear palsy: can measurement of tau forms help?â€• Neurobiology of Aging, 2012, 33, 1839-1840.	1.5	1
42	Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiology of Aging, 2012, 33, 2138-2144.	1.5	60
43	Synaptic Dysfunction in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2012, 970, 573-601.	0.8	94
44	Increased [³H]Dâ€aspartate release and changes in glutamate receptor expression in the hippocampus of the mnd mouse. Journal of Neuroscience Research, 2012, 90, 1148-1158.	1.3	4
45	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinsonâ€™s disease. Brain, 2012, 135, 1884-1899.	3.7	124
46	Cerebrospinal Fluid Tau in Frontotemporal Lobar Degeneration: Clinical, Neuroimaging, and Prognostic Correlates. Journal of Alzheimer's Disease, 2011, 23, 505-512.	1.2	9
47	European neuroscience research: the road ahead.... European Journal of Neuroscience, 2011, 33, 767-767.	1.2	1
48	Consensus Document on European Brain Research. European Journal of Neuroscience, 2011, 33, 768-818.	1.2	29
49	Effect of rasagiline on the molecular composition of the excitatory postsynaptic density. European Journal of Pharmacology, 2011, 670, 458-463.	1.7	4
50	Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia. Experimental Neurology, 2011, 232, 240-250.	2.0	39
51	Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1Î² and NMDA stimulation. Journal of Neuroinflammation, 2011, 8, 14.	3.1	106
52	Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiology of Disease, 2011, 43, 507-515.	2.1	91
53	Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease. Current Medicinal Chemistry, 2011, 18, 2655-2660.	1.2	13
54	Genetic Background Predicts Poor Prognosis in Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2011, 8, 289-295.	0.8	17

#	Article	IF	Citations
55	Searching for new animal models of Alzheimerâ€²s disease. European Journal of Pharmacology, 2010, 626, 57-63.	1.7	44
56	Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Experimental Gerontology, 2010, 45, 53-56.	1.2	76
57	Role of Glycogen Synthase Kinase-3Î² in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons. Pharmaceuticals, 2010, 3, 42-58.	1.7	6
58	Cognitive Deficits Associated with Alteration of Synaptic Metaplasticity Precede Plaque Deposition in AÎ²PP23 Transgenic Mice. Journal of Alzheimer's Disease, 2010, 21, 1367-1381.	1.2	35
59	Synaptic Activity Controls Dendritic Spine Morphology by Modulating eEF2-Dependent BDNF Synthesis. Journal of Neuroscience, 2010, 30, 5830-5842.	1.7	128
60	Synaptic Localization and Activity of ADAM10 Regulate Excitatory Synapses through N-Cadherin Cleavage. Journal of Neuroscience, 2010, 30, 16343-16355.	1.7	102
61	An Arginine Stretch Limits ADAM10 Exit from the Endoplasmic Reticulum. Journal of Biological Chemistry, 2010, 285, 10376-10384.	1.6	53
62	A Combination of CSF Tau Ratio and Midsaggital Midbraintopons Atrophy for the Early Diagnosis of Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2010, 22, 195-203.	1.2	18
63	Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition. Journal of Neuroscience, 2010, 30, 14182-14193.	1.7	155
64	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimerâ€™s disease. Brain, 2010, 133, 3323-3335.	3.7	71
65	Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinsonâ€™s disease. Progress in Brain Research, 2010, 183, 169-182.	0.9	41
66	New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum. Current Medicinal Chemistry, 2010, 17, 1002-1009.	1.2	12
67	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. Biological Psychiatry, 2010, 67, 567-574.	0.7	68
68	Establishing short-term prognosis in Frontotemporal Lobar Degeneration spectrum: Role of genetic background and clinical phenotype. Neurobiology of Aging, 2010, 31, 270-279.	1.5	28
69	Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression. Journal of Neuroscience, 2009, 29, 669-677.	1.7	126
70	Mutation withinTARDBPleads to Frontotemporal Dementia without motor neuron disease. Human Mutation, 2009, 30, E974-E983.	1.1	220
71	Epilepsyâ€induced abnormal striatal plasticity in Bassoon mutant mice. European Journal of Neuroscience, 2009, 29, 1979-1993.	1.2	26
72	Linking supply to demand: the neuronal monocarboxylate transporter MCT2 and the Î±â€aminoâ€3â€hydroxylâ€5â€methylâ€4â€isoxazoleâ€propionic acid receptor GluR2/3 subunit are associated in a common trafficking process. European Journal of Neuroscience, 2009, 29, 1951-1963.	1.2	34

#	Article	IF	Citations
73	Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiology of Aging, 2009, 30, 34-40.	1.5	85
74	Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiology of Aging, 2009, 30, 1406-1412.	1.5	69
75	Postsynaptic densityâ€“membrane associated guanylate kinase proteins (PSDâ€“MAGUKs) and their role in CNS disorders. Neuroscience, 2009, 158, 324-333.	1.1	64
76	BDNF Genetic Variations Increase the Risk of Alzheimer's Disease-Related Depression. Journal of Alzheimer's Disease, 2009, 18, 867-875.	1.2	56
77	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics, 2008, 9, 197-205.	0.7	63
78	Tau haplotype influences cerebral perfusion pattern in frontotemporal lobar degeneration and related disorders. Acta Neurologica Scandinavica, 2008, 117, 359-366.	1.0	15
79	Amyloid flirting with synaptic failure: Towards a comprehensive view of Alzheimer's disease pathogenesis. European Journal of Pharmacology, 2008, 585, 109-118.	1.7	52
80	Modulatory effect of acetyl-l-carnitine on amyloid precursor protein metabolism in hippocampal neurons. European Journal of Pharmacology, 2008, 597, 51-56.	1.7	24
81	Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor composition in rat striatum. European Neuropsychopharmacology, 2008, 18, 531-534.	0.3	12
82	Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394.	3.7	223
83	Preliminary Evidence that VEGF Genetic Variability Confers Susceptibility to Frontotemporal Lobar Degeneration. Rejuvenation Research, 2008, 11, 773-780.	0.9	23
84	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology, 2008, 71, 1796-1803.	1.5	101
85	Brain Magnetic Resonance Imaging Structural Changes in a Pedigree of Asymptomatic Progranulin Mutation Carriers. Rejuvenation Research, 2008, 11, 585-595.	0.9	87
86	Combined Biomarkers for Early Alzheimer Disease Diagnosis. Current Medicinal Chemistry, 2007, 14, 1171-1178.	1.2	31
87	Evidence of White Matter Changes on Diffusion Tensor Imaging in Frontotemporal Dementia. Archives of Neurology, 2007, 64, 246.	4.9	123
88	The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology, 2007, 68, 624-624.	1.5	6
89	Synapse-Associated Protein-97 Mediates Â-Secretase ADAM10 Trafficking and Promotes Its Activity. Journal of Neuroscience, 2007, 27, 1682-1691.	1.7	164
90	SAP97 Directs the Localization of Kv4.2 to Spines in Hippocampal Neurons. Journal of Biological Chemistry, 2007, 282, 28691-28699.	1.6	40

#	Article	IF	Citations
91	Neonatal Exposure to Brominated Flame Retardant BDE-47 Reduces Long-Term Potentiation and Postsynaptic Protein Levels in Mouse Hippocampus. Environmental Health Perspectives, 2007, 115, 865-870.	2.8	115
92	Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A. Journal of Neurochemistry, 2007, 100, 1032-1046.	2.1	67
93	Latent profile analysis in frontotemporal lobar degeneration and related disorders: clinical presentation and SPECT functional correlates. BMC Neurology, 2007, 7, 9.	0.8	14
94	Cumulative Effect of COMT and 5-HTTLPR Polymorphisms and Their Interaction With Disease Severity and Comorbidities on the Risk of Psychosis in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2006, 14, 343-351.	0.6	29
95	Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiology of Aging, 2006, 27, 24-31.	1.5	139
96	Genetic correlates of behavioral endophenotypes in Alzheimer disease: Role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiology of Aging, 2006, 27, 1595-1603.	1.5	73
97	NMDA Receptor Composition Differs Among Anatomically Diverse Malformations of Cortical Development. Journal of Neuropathology and Experimental Neurology, 2006, 65, 883-893.	0.9	48
98	NR2B Subunit Exerts a Critical Role in Postischemic Synaptic Plasticity. Stroke, 2006, 37, 1895-1901.	1.0	63
99	Calcium-calmodulin-dependent protein kinaseâ€ƒII phosphorylation modulates PSD-95 binding to NMDA receptors. European Journal of Neuroscience, 2006, 24, 2694-2704.	1.2	82
100	Tau haplotype affects CSF Tau levels in frontotemporal dementia. Journal of Neurology, 2006, 253, 946-946.	1.8	1
101	New targets for pharmacological intervention in the glutamatergic synapse. European Journal of Pharmacology, 2006, 545, 2-10.	1.7	136
102	Predicting Alzheimer dementia in mild cognitive impairment patients. European Journal of Pharmacology, 2006, 545, 73-80.	1.7	47
103	Functional correlates of Apolipoprotein E genotype in Frontotemporal Lobar Degeneration. BMC Neurology, 2006, 6, 31.	0.8	16
104	Expression of AMPA and NMDA receptor subunits in the cervical spinal cord of wobbler mice. BMC Neuroscience, 2006, 7, 71.	0.8	25
105	A Critical Interaction between NR2B and MAGUK in L-DOPA Induced Dyskinesia. Journal of Neuroscience, 2006, 26, 2914-2922.	1.7	243
106	Interleukin-1Î² Released by gp120 Drives Neural Death through Tyrosine Phosphorylation and Trafficking of NMDA Receptors. Journal of Biological Chemistry, 2006, 281, 30212-30222.	1.6	107
107	Analytical performance and clinical utility of the INNOTESTÂ® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1472-80.	1.4	145
108	Catechol-o-methyltransferase gene polymorphism in dementia with Lewy bodies-related psychosis: evidence for a genetic predisposition. International Psychogeriatrics, 2006, 18, 755-757.	0.6	3

#	Article	IF	Citations
109	Advances On Biological Markers In Early Diagnosis Of Alzheimer Disease. Advances in Clinical Chemistry, 2005, 39, 107-129.	1.8	2
110	Preâ€“clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. Journal of Neurology, 2005, 252, 1359-1362.	1.8	34
111	Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiology of Disease, 2005, 19, 237-242.	2.1	60
112	Artificial neural networks allow the use of simultaneous measurements of Alzheimer disease markers for early detection of the disease. Journal of Translational Medicine, 2005, 3, 30.	1.8	30
113	Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients. Journal of the Neurological Sciences, 2005, 229-230, 211-213.	0.3	17
114	Management of Glaucoma: Focus on Pharmacological Therapy. Drugs and Aging, 2005, 22, 1-21.	1.3	166
115	Molecular Rationale for the Pharmacological Treatment of Alzheimer??s Disease. Drugs and Aging, 2005, 22, 27???37.	1.3	30
116	Calcium/Calmodulin-dependent Protein Kinase II Phosphorylation Drives Synapse-associated Protein 97 into Spines. Journal of Biological Chemistry, 2004, 279, 23813-23821.	1.6	81
117	Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. Journal of Neurochemistry, 2004, 90, 1489-1499.	2.1	129
118	Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neuroscience Letters, 2004, 370, 127-129.	1.0	55
119	Advance on the diagnostic potential of biological markers in the early detection of Alzheimer Disease. Neuroscience Research Communications, 2004, 35, 232-245.	0.2	3
120	Abnormal Ca2+-Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism. Journal of Neuroscience, 2004, 24, 5283-5291.	1.7	136
121	Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinergic hypofunction in rats. Experimental Neurology, 2004, 189, 162-172.	2.0	84
122	Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 763-770.	2.5	32
123	Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiology of Disease, 2004, 16, 454-460.	2.1	103
124	Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators. Neurobiology of Aging, 2004, 25, 747-751.	1.5	78
125	Predicting Cognitive Decline in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2004, 18, 32-34.	0.6	23
126	NMDA receptors. , 2004, , 51-63.		1

#	Article	IF	Citations
127	Molecular biology of postsynaptic structures. , 2004, , 165-180.		0
128	Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease. Neuroscience Letters, 2003, 343, 213-215.	1.0	29
129	High cholesterol affects platelet APP processing in controls and in AD patients. Neurobiology of Aging, 2003, 24, 631-636.	1.5	24
130	CaMKII-dependent Phosphorylation Regulates SAP97/NR2A Interaction. Journal of Biological Chemistry, 2003, 278, 44745-44752.	1.6	95
131	Longâ€lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity. Involvement of the NMDA receptor complex. FASEB Journal, 2003, 17, 1-22.	0.2	66
132	Neurogenesis in Cerebral Heterotopia Induced in Rats by Prenatal Methylazoxymethanol Treatment. Cerebral Cortex, 2003, 13, 736-748.	1.6	37
133	Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type. Archives of Neurology, 2003, 60, 1740.	4.9	63
134	Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors. Journal of Biological Chemistry, 2003, 278, 20196-20202.	1.6	200
135	The NMDA Receptor Complex Is Altered in an Animal Model of Human Cerebral Heterotopia. Journal of Neuropathology and Experimental Neurology, 2003, 62, 662-675.	0.9	30
136	Abnormalities in the Pattern of Platelet Amyloid Precursor Protein Forms in Patients With Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2002, 59, 71.	4.9	92
137	Peripheral Blood Abnormalities in Alzheimer Disease: Evidence for Early Endothelial Dysfunction. Alzheimer Disease and Associated Disorders, 2002, 16, 150-155.	0.6	33
138	Microvascular damage and platelet abnormalities in early Alzheimer's disease. Journal of the Neurological Sciences, 2002, 203-204, 189-193.	0.3	43
139	Synaptic plasticity in the diabetic brain: advanced aging?. Progress in Brain Research, 2002, 138, 305-314.	0.9	23
140	ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. European Neuropsychopharmacology, 2002, 12, 195-200.	0.3	51
141	euroSCIENCE moves into sixth gear!. Trends in Neurosciences, 2002, 25, 591-594.	4.2	1
142	Î±-Secretase ADAM10 as Well as Î±APPs Is Reduced in Platelets and CSF of Alzheimer Disease Patients. Molecular Medicine, 2002, 8, 67-74.	1.9	215
143	Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms. Neurological Sciences, 2002, 23, 207-210.	0.9	22
144	Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats. Journal of Neurochemistry, 2002, 80, 438-447.	2.1	112

#	Article	IF	Citations
145	Î±CaMKII and NMDA-Receptor Subunit Expression in Epileptogenic Cortex from Human Periventricular Nodular Heterotopia. Epilepsia, 2002, 43, 209-216.	2.6	30
146	Lack of PSD-95 drives hippocampal neuronal cell death through activation of an Î±CaMKII transduction pathway. European Journal of Neuroscience, 2002, 16, 777-786.	1.2	42
147	Increased Secretion of the Amino-Terminal Fragment of Amyloid Precursor Protein in Brains of Rats with a Constitutive Up-Regulation of Protein Kinase C. Journal of Neurochemistry, 2002, 68, 2523-2529.	2.1	47
148	[alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Molecular Medicine, 2002, 8, 67-74.	1.9	88
149	NMDA receptor subunits are phosphorylated by activation of neurotrophin receptors in PSD of rat spinal cord. NeuroReport, 2001, 12, 1301-1305.	0.6	38
150	Hippocampal Synaptic Plasticity Involves Competition between Ca²⁺/Calmodulin-Dependent Protein Kinase II and Postsynaptic Density 95 for Binding to the NR2A Subunit of the NMDA Receptor. Journal of Neuroscience, 2001, 21, 1501-1509.	1.7	162
151	Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target. Mechanisms of Ageing and Development, 2001, 122, 1997-2004.	2.2	24
152	Protein Kinase C Activation Modulates Î±-Calmodulin Kinase II Binding to NR2A Subunit of N-Methyl-D-Aspartate Receptor Complex. Journal of Biological Chemistry, 2001, 276, 7609-7613.	1.6	98
153	Amyloid Precursor Protein in Platelets of Patients With Alzheimer Disease. Archives of Neurology, 2001, 58, 442-6.	4.9	75
154	(+)-MCPG induces PKCÎµ translocation in cortical synaptosomes through a PLD-coupled mGluR. European Journal of Neuroscience, 2000, 12, 1310-1318.	1.2	16
155	Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. European Journal of Pharmacology, 2000, 405, 277-283.	1.7	74
156	Presenilin 2 Mutation Does Not Influence Expression and Concentration of APP Forms in Human Platelets. Molecular Medicine, 2000, 6, 816-824.	1.9	6
157	Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord. Human Molecular Genetics, 2000, 9, 47-56.	1.4	129
158	NMDA receptor subunits are modified transcriptionally and post-translationally in the brain of streptozotocin-diabetic rats. Diabetologia, 1999, 42, 693-701.	2.9	100
159	Pathophysiological implications of the structural organization of the excitatory synapse. European Journal of Pharmacology, 1999, 375, 339-347.	1.7	15
160	Î±CaMKII binding to the C-terminal tail of NMDA receptor subunit NR2A and its modulation by autophosphorylation. FEBS Letters, 1999, 456, 394-398.	1.3	101
161	Prenatal Methylazoxymethanol Treatment in Rats Produces Brain Abnormalities with Morphological Similarities to Human Developmental Brain Dysgeneses. Journal of Neuropathology and Experimental Neurology, 1999, 58, 92-106.	0.9	104
162	Nicergoline and its metabolite induce translocation of PKC isoforms in selective rat brain areas. Neuroscience Research Communications, 1998, 23, 159-167.	0.2	11

#	Article	IF	Citations
163	Altered connections between neocortical and heterotopic areas in methylazoxymethanol-treated rat. Epilepsy Research, 1998, 32, 49-62.	0.8	69
164	Dysplastic neocortex and subcortical heterotopias in methylazoxymethanol-treated rats: an intracellular study of identified pyramidal neurones. Neuroscience Letters, 1998, 246, 181-185.	1.0	64
165	Calcium/Calmodulinâ€Ðependent Protein Kinase II Is Associated with NR2A/B Subunits of NMDA Receptor in Postsynaptic Densities. Journal of Neurochemistry, 1998, 71, 1733-1741.	2.1	165
166	Differential Level of Platelet Amyloid beta Precursor Protein Isoforms: An Early Marker for Alzheimer Disease. Archives of Neurology, 1998, 55, 1195-1200.	4.9	146
167	Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiological Reviews, 1997, 77, 199-215.	13.1	116
168	Increased Presynaptic Protein Kinase C Activity and Glutamate Release in Rats with a Prenatally Induced Hippocampal Lesion. European Journal of Neuroscience, 1997, 9, 472-479.	1.2	16
169	Levels of NGF, p75NGFR and ChAT immunoreactivity in brain of adult and aged microencephalic rats. Neurobiology of Aging, 1996, 17, 137-142.	1.5	22
170	Determination of the endogenous phosphorylation state of B-50/GAP-43 and neurogranin in different brain regions by electrospray mass spectrometry. FEBS Letters, 1996, 389, 309-313.	1.3	15
171	Differential translocation of protein kinase C isozymes in rats characterized by a chronic lack of LTP induction and cognitive impairment. FEBS Letters, 1996, 393, 121-123.	1.3	12
172	Abnormal Pattern of Platelet APP Isoforms in Alzheimer Disease and Down Syndrome. Archives of Neurology, 1996, 53, 1162-1166.	4.9	80
173	Selective in vitro blockade of neuroepithelial cells proliferation by methylazoxymethanol, a molecule capable of inducing long lasting functional impairments. Journal of Neuroscience Research, 1995, 41, 640-647.	1.3	55
174	Selective alteration in B-50/GAP-43 phosphorylation in brain areas of animals characterized by cognitive impairment. Brain Research, 1993, 607, 329-332.	1.1	14
175	The impaired long-term potentiation in the CA1 field of the hippocampus of cognitive deficient microencephalic rats is restored byd-serine. Neuroscience, 1993, 54, 49-60.	1.1	44
176	Cellular expression of somatostatin in MAM-induced microencephaly in the rat. Developmental Brain Research, 1992, 70, 39-46.	2.1	5
177	Measurement of relative amounts of phospho- and dephospho-B-50(GAP-43) peptides by fast atom bombardment-mass spectrometry. FEBS Letters, 1992, 301, 150-154.	1.3	4
178	Microencephaly reduces the phosphorylation of the PKC substrate B-50/GAP43 in rat cortex and hippocampus. Brain Research, 1991, 538, 95-101.	1.1	17
179	Î²-Adrenoceptor desensitization induced by antigen challenge in guinea-pig trachea. European Journal of Pharmacology, 1990, 178, 21-27.	1.7	3
180	In vivo modulation of striatal phosphoproteins by dopaminergic agents. European Journal of Pharmacology, 1989, 172, 321-328.	2.7	6

#	Article	IF	Citations
181	Denervation and hyperinnervation in the nervous system of diabetic animals: III. Functional alterations of G proteins in diabetic encephalopathy. Journal of Neuroscience Research, 1989, 24, 517-523.	1.3	27
182	Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase. Pharmacological Research Communications, 1987, 19, 275-286.	0.2	26